Abstract: The present invention is related to complex peptide mixtures with immunomodulatory effects and methods for their use. The invention is further directed toward treatments of diseases through the modulation of the immune system with complex peptide mixtures. The invention is also directed to methods for improving the characteristics of complex peptide mixtures.

Abstract: A variety of therapies are used to treat autoimmune diseases such as multiple sclerosis. However, there is no single therapy that can be used to treat all subjects. Thus, a method is provided to determine if a subject with an autoimmune disease, such as multiple sclerosis, will respond to a therapeutic protocol. The method includes analyzing the expression of genes expressed by the immune system. Although the expression of a single gene can be assessed, such as interleukin-8, the methods include evaluating the expression profile of a subject using an array (such as a microarray) to determine if the subject is appropriately responding to the therapeutic protocol.

Abstract: The invention relates to carbacyclin derivatives of Formula I ##STR1## wherein the various substituents are defined herein, including, inter alia,if R.sub.2 is a hydrogen atom, their salts with physiologically compatible bases, their cyclodextrin clathrates, and their use as medicinal agents.

Abstract: 5-fluorocarbacyclin derivatives of the Formula I ##STR1## wherein R.sub.1 is CH.sub.2 OH orA is --CH.sub.2 --CH.sub.2 --, trans --CH.dbd.CH-- or --C.tbd.C--,W is a free or functionally modified hydroxymethylene group or free or functionally modified ##STR2## in which the OH group can be in the .alpha.-- or .beta.-position, D is ##STR3## a C.sub.1-10 -aliphatic group (e.g., alkyl or alkenyl) which optionally can be substituted by fluorine atoms,n is 1, 2 or 3,E is a direct bond, --C.tbd.C-- or --CR.sub.6 .tbd.CR.sub.7 -- in which R.sub.6 represents a hydrogen atom or an alkyl group with 1-5 atoms and R.sub.7 represents a hydrogen atom, a halogen atom or an alkyl group with 1-5 C atoms,R.sub.4 is alkyl, cycloalkyl or optionally substituted aryl or a heterocyclic group,R.sub.5 is a free or functionally modified hydroxy groupand, when R.sub.2 is a hydrogen atom, its salts with physiologically compatible bases,have valuable pharmacological properties.

Abstract: The invention relates to 7-oxoprostacyclin derivatives of Formula I ##STR1## wherein R.sub.1 is the residue OR.sub.3 wherein R.sub.3 can mean hydrogen or alkyl of 1-10 carbon atoms optionally substituted by halogen, phenyl, C.sub.1 -C.sub.4 -alkoxy or C.sub.1 -C.sub.4 -dialkylamino, or the residue NHR.sub.4 meaning an alkanoyl or alkanesulfonyl residue of respectively 1-10 carbon atoms,W is a hydroxymethylene or a ##STR2## group wherein the OH-group can be respectively esterified with a benzoyl or alkanoic acid residue of 1-4 carbon atoms or etherified with a tetrahydropyranyl, tetrahydrofuranyl, (C.sub.1 -C.sub.4 -alkoxy)-C.sub.1 -C.sub.4 -alkyl or tri-(C.sub.1 -C.sub.4 -alkyl)-silyl residue, wherein the free or modified OH-group can be in the .alpha.- or .beta.- position,D is a straight-chain or branched alkylene group of 1-5 carbon atoms,R.sub.2 is a straight-chain or branched alkyl group of 1-6 carbon atoms,R.sub.

Abstract: The invention relates to a combination preparation for thrombosis treatment consisting of acetylsalicylic acid and carbacyclin derivatives.

Abstract: The invention relates to carbacyclin derivatives of Formula I ##STR1## wherein the various substituents are defined herein, including, inter alia,if R.sub.2 means a hydrogen atom,their salts with physiologically compatible bases, their cyclodextrin clathrates, processes for their preparation, and their use as medicinal agents.

Abstract: The invention relates to 6-oxo-prostaglandin E.sub.1 derivatives of formula I, ##STR1## in which R.sup.1 means the radical COOR.sup.2 with R.sup.2 meaning a hydrogen atom, C.sub.1 -C.sub.10 alkyl, a C.sub.5 -C.sub.6 cycloalkyl or a C.sub.6 -C.sub.10 aryl group or a heterocyclic radical, or the radical CONHSO.sub.2 R.sup.5 as C.sub.1-10 alkyl, C.sub.5-6 cycloalkyl or C.sub.6-10 aryl,A means an E-configuration CH.dbd.CH or a --C.dbd.C group,W means a free or functionally modified hydroxymethylene group or a free or functionally modified group, and the OH group in each case can be in the alpha or beta position,D means a straight-chain or branched-chain alkylene group with 1-5 C atoms,E means a --C.dbd.C group or a C.sub.2 -C.sub.4 alkenylene group,R.sup.3 means C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 cycloalkyl or an optionally substituted C.sub.6 -C.sub.10 aryl group or a heterocyclic group,R.sup.4 means a free or functionally modified hydroxy group, and if R.sup.

Abstract: 11-Haloprostane derivatives of general Formula I ##STR1## wherein X is F, Cl or Br,R.sub.1 is the residue CH.sub.2 OH or ##STR2## wherein R.sub.2 means a hydrogen atom, an alkyl, cycloalkyl, aryl, phenacyl or heterocyclic residue,A is a --CH.sub.2 --CH.sub.2 -- or cis--CH.dbd.CH--group,B is a --CH.sub.2 --CH.sub.2 -- or trans--CH.dbd.CH-- or a --C.tbd.C--group,W is an ethylenedioxymethylene group or a hydroxymethylene group,D and E together mean a direct bond orD is a C.sub.1-10 -alkylene group,E is an oxygen or sulfur atom, a direct bond, a --C.tbd.C--bond or a --CR.sub.6 .dbd.CR.sub.7 -group with R.sub.6 and R.sub.7 meaning a hydrogen atom, a chlorine atom or an alkyl group,R.sub.4 is a hydroxy group,R.sub.5 is a hydrogen atom, an alkyl, a cycloalkyl, an aryl or a heterocyclic group, andthe salts thereof with physiologically compatible bases, processes for their preparation, and use thereof as agents inhibiting gastric acid secretion.

Abstract: 11-Haloprostane derivatives of general formula I ##STR1## wherein X is F, Cl or Br,R.sub.1 is the residue CH.sub.2 OH or ##STR2## wherein R.sub.2 means a hydrogen atom, an alkyl, cycloalkyl, aryl, phenacyl or heterocyclic residue,A is a --CH.sub.2 --CH.sub.2 -- or cis-CH.dbd.CH-group,B is a --CH.sub.2 --CH.sub.2 -- or trans-CH.dbd.CH-- or a --C.tbd.C-group,W is an ethylenedioxymethylene group or a hydroxymethylene group,D and E together mean a direct bond orD is a C.sub.1-10 -alkylene group,E is an oxygen or sulfur atom, a direct bond, a --C.tbd.C-bond or a --CR.sub.6 .dbd.CR.sub.7 -group with R.sub.6 and R.sub.7 meaning a hydrogen atom, a chlorine atom or an alkyl group,R.sub.4 is a hydroxy group,R.sub.5 is a hydrogen atom, an alkyl, a cycloalkyl, an aryl or a heterocyclic group, andthe salts thereof with physiologically compatible bases, processes for their preparation, and use thereof as agents inhibiting gastric acid secretion.